Phaseline

Companies › LB Pharmaceuticals

LB Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Psychiatry; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LB-102
Atypical antipsychotic; dopamine D2/D3 receptor antagonist
DRD2, DRD3Phase 3Schizophrenia; Bipolar I DisorderJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07363577LB-102Phase 3SchizophreniaPsychiatryJun 2027
NCT07494305LB-102Phase 2Bipolar I DisorderPsychiatryFeb 2028
NCT07369154LB-102Phase 3SchizophreniaPsychiatryDec 2028

From the company's SEC filings

Cash and short-term investments of $403m on 2026-09-30; operating cash outflow about $168m a year; runway about 29 months at that burn, to Feb 2029; 3 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

DRD2 (1) DRD3 (1)

Companies with the same targets

Gedeon Richter Serina Therapeutics Boryung Pharmaceutical Anxo Pharmaceutical Mapi Pharma AbbVie MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals Prilenia Changchun GeneScience Pharmaceutical Vanda Pharmaceuticals

Companies built like this

Gedeon Richter Reviva Pharmaceuticals Minerva Neurosciences Cybin IRL Beijing Union Pharmaceutical Factory

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.